Ebola treatment trial for Bundibugyo strain in Congo's Ituri province
Consensus Summary
A clinical trial testing two experimental Ebola treatments, remdesivir and MBP134, has begun in Bunia, Congo, to combat the largest-ever Bundibugyo outbreak. The trial, a collaboration between Congoâs INRB, Oxford University, and Antwerpâs Institute of Tropical Medicine, aims to improve survival rates by tracking patients for 28 days after treatment. Both sources agree the trial could last six or more months and includes high-risk groups like healthcare workers. However, discrepancies exist in reported case and death figures, with ABC citing 1,400 cases and 438 deaths at the trialâs start, while the Guardian reports 1,792 cases and 625 deaths as of 9 July. The Guardian also highlights the rapid setup of the trial, begun just six weeks after the WHO declared a public health emergency on 17 May, contrasting with slower responses in past outbreaks like the 2014-16 West Africa crisis, which saw over 28,000 cases and 11,000 deaths. Community reactions vary, with some residents hopeful for quick results while others distrust the treatments, and frontline workers protesting over unpaid wages.
â Verified by 2+ sources
Key details reported by multiple sources:
- A clinical trial testing remdesivir and MBP134 for Bundibugyo Ebola began in Bunia, eastern Congo's Ituri province
- The trial involves testing two drugs (remdesivir and MBP134) individually or in combination to improve survival rates among infected patients
- The trial will track survival for 28 days after treatment begins
- The trial is a collaboration between Congo's INRB, Britain's Oxford University, and Antwerp's Institute of Tropical Medicine
- The trial could last six or more months depending on the outbreak's evolution
- The Bundibugyo strain has no approved vaccine or specific treatment and has a high fatality rate
- The trial includes patients of any age, including pregnant and breastfeeding women
Points of Difference
Details reported by only one source:
- WHO reported 1,400 diagnosed cases and 438 deaths from Bundibugyo as of the trial's start
- The trial's second phase will include healthcare workers, close contacts, and others at high risk of infection
- Some Bunia residents welcome the trial, while others distrust it, fearing the treatments could cause more deaths
- A resident named Audrey Tengetenge called the trial a 'light at the end of the tunnel' and hoped for quick results
- Another resident, Gladys Munguro, a survivor of Ebola, plans to volunteer for the high-risk phase of the trial
- The trial was set up and started in just six weeks after the outbreak was declared a public health emergency on 17 May
- As of 9 July, there were 1,792 confirmed cases and 625 deaths from Bundibugyo
- The trial requires between 700 and 1,000 patients to determine effectiveness, with enough remdesivir and MBP134 donated for 1,200 patients
- Frontline workers in Rwampara protested due to lack of pay, with some attacked by local people; payments were reportedly made but unclear if activities resumed
- A second trial is due to begin this week testing obeldesivir to prevent infection in contacts of Bundibugyo cases
- The 2014-16 West Africa Ebola outbreak saw over 28,000 cases and 11,000 deaths, with trials taking over a year to start
- The trial is sponsored by the WHO, with funding from the Wellcome Trust, FCDO, and UKRI
Contradictions
Conflicting information between sources:
- ABC reports 1,400 cases and 438 deaths as of the trial's start, while the Guardian reports 1,792 cases and 625 deaths as of 9 July
- ABC mentions the trial began on Thursday, while the Guardian states patients were enrolled just six weeks after the WHO declared a public health emergency on 17 May
- The Guardian notes the trial requires 700 and 1,000 patients, while ABC mentions a possible 1,000 participants without specifying a range
- The Guardian specifies the trial began in early May (17 May declaration, six weeks later), while ABC does not provide a specific start date beyond 'Thursday'
Source Articles
Ebola treatment trial begins in Congo as outbreak continues to grow
A trial for an experimental Ebola treatment starts in Congo, where the largest-ever Ebola outbreak continues to grow.
First patients enrolled in record-breaking Ebola treatment trial in DRC
Two drugs are being trialled in the Ituri region in a programme set up just six weeks after the outbreak was declared, with hopes it will reduce mortality rates There is no approved drug to help the medical teams scrabbling to save lives in the Ebola outbreak in the Democratic Republic of the Congo â but there are hopes that could change within months as the first patients are enrolled in a treatment trial. It is a record pace to set up and start this kind of research, scientists said, with pati